Default company panoramic image

Viewpoint Molecular Targeting

Viewpoint has developed a patented image-guided therapy for metastatic melanoma that is poised for Phase I clinical trials in humans.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Iowa City, IA, USA
  • Currency USD
  • Founded October 2008
  • Employees 3
  • Website

Company Summary

Viewpoint develops injectable radiopharmaceuticals for diagnosis and therapy for cancer, with a focus on metastatic melanoma. Our products target cancer-cell specific properties, enabling a personalized-image-guided approach to optimizing treatments. Viewpoint has invented or licenses a portfolio of compounds at the preclinical and clinical stage of development, with its lead product poised to enter Phase I clinical imaging trials in humans.


  • Default avatar
    Michael K Schultz PhD
    Chief Science Officer

    Michael Schultz PhD is a founding member and CSO of Viewpoint. Dr. Schultz is also an Assistant Professor of Radiology at the University of Iowa. Dr. Schultz specializes in targeted diagnostic imaging and therapy for cancer. Dr. Schultz is experienced in IND submission to the FDA for approval of diagnostics and therapies, including the first gallium-68 labeled peptide for clinical human studies in the US and a successful IND for cancer therapy.

  • Default avatar
    Heyward H Coleman MBA
    Chief Operating Officer

    Heyward Coleman is Chief Executive Officer and a founding member of Viewpoint. Mr Coleman earned a MS in Nuclear Engineering from Duke University and an MBA from Harvard University. After a successful career in oil and gas, Mr. Coleman became a serial entrepreneur, founding the largest privately owned radiochemistry company in the US, among other projects. Mr Coleman directs operations, oversees finances, and manages strategic partnerships.

  • Default avatar
    Frances L Johnson MD
    Chief Medical Officer

    Frances Johnson MD is a founding member and Chief Medical Officer of Viewpoint. Dr Johnson's training includes an MD from University of Washington, residency at UC, San Francisco, followed by a fellowship and faculty appointment (Asst Prof) at Stanford. Dr Johnson has been involved in two successful biotech startups including XDx, Inc. Dr. Johnson is experienced in clinical trials and commercializing discoveries for diagnostics and therapies.

  • Default avatar
    Ebrahim Delpassand MD
    Advisory Board Member

    Ebrahim S. Delpassand MD is the founder and CEO of RadioMedix. Dr. Delpassand served 12 years as Deputy Chairman and Chief of Nuclear Medicine at the MD Anderson Cancer Center (University of TX), where he managed 65 technical staff and administrators and revenues of $50 million per year. Since that time Dr Delpassand has been a serial entrepreneur in healthcare and oncology, founding several successful businesses, most recently Radiomedix, Inc.

  • Default avatar
    Michael Graham MD PhD
    Advisory Board Member

    Dr. Graham is Professor and Vice Chair of Radiology and Director of Nuclear Medicine at the University of Iowa and is board certified. Dr. Graham's earned degrees from MIT (BSEE) and UC Berkeley (MSEE), followed by a PhD (Biophysics) from UC Berkeley, and MD from UCSF. He is past President of the Society of Nuclear Medicine and Co-Chair of the SNMMI Clinical Trials Network. Dr Graham has published over 178 papers, 9 chapters and 141 abstracts.